510(k) Summary (page 1 of 2)

Submitter's Name and Address:

Mitek Worldwide

249 Vanderbilt Avenue Norwood, MA 02062 Registration #1221934

Contact Person:

Petra Smit, RAC,

Sr. Project Manager Regulatory Affairs

Phone Number:

781-251-3196

Telefax Number:

781-278-9578

Date Summary Prepared:

October 8, 2002

Device Trade Name:

Mitek RAPIDLOC-PDS Meniscal Repair

System

Common name:

Biodegradable Fixation Fastener

Classification Name:

Fastener, Fixation, Biodegradable Soft Tissue

(Class II, 21 CFR 888.3030, Product code: 87

MAI)

Predicate Device(s):

RAPIDLOC Meniscal Repair System

(K002406)

Mitek "H"-Fix Meniscal Fastener (K970119)

Device Description:

The RAPIDLOC-PDS Meniscal Repair System consists of a two piece (polydiaxonone tophat and polylactic acid backstop) bioabsorbable meniscal tissue fixation implant mounted on a 2/0 pre-knotted PANACRYL braided long-term

absorbable suture. It is applied using a cannulated needle and arthroscopic pusher.

Intended Use:

The RAPIDLOC-PDS Meniscal Repair System is intended for use in the arthroscopic fixation of longitudinal vertical meniscus lesions (buckethandle lesions) located in the vascularized area of the meniscus (red-red and red-white areas).

510(k) Summary (page 2 of 2)

Technological Characteristics: The proposed device has similar technological

characteristics and is similar in design and configuration compared to the predicate devices.

Summary of Non-clinical Test: Testing conducted to characterize performance

of the RAPIDLOC-PDS Meniscal Repair System has demonstrated that it is substantially equivalent to the predicate devices and is

suitable for the intended use specified.

Clinical Data: Not Applicable

Conclusion: Based on 1) safety and performance data, and 2)

similarities in design, operating principles, biocompatibility and sterilization method, the Mitek RAPIDLOC-PDS Meniscal Repair System has been shown to be substantially equivalent to predicate devices under the Federal Food, Drug and Cosmetic Act.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 2 7 2002

Ms. Petra C. Smit Sr. Project Manager, Regulatory Affairs Mitek Worldwide 249 Vanderbilt Avenue Norwood, Massachusetts 02062

Re: K023388

Trade/Device Name: Mitek RAPIDLOC-PDS Meniscal Repair System

Regulation Number: 21 CFR 888.3030

Regulation Name: Single/Multiple Component Metallic Bone Fixation Appliances and

Accessories

Regulatory Class: Class II

Product Code: JDR

Dated: December 5, 2002 Received: December 6, 2002

Dear Ms. Smit:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Mark of Miller

Director

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

	Page 1 01 1			
			• • • •	• • •
510(k) Number (if known):	K023388	8		•
Device Name: RAPIDLOC-P			<u>a</u>	
	•	<i>:</i>	•••	
Indications for Use:				
The RAPIDLOC-PDS Menise fixation of longitudinal vertical vascularized area of the menisc	l meniscus lesio	ons (bucket-ha	andle lesions) lo	
(PLEASE DO NOT WRITE BI IF NEEDED)	ELOW THIS L	LINE - CONT	INUE ON ANC	OTHER PAGE
Concurrence of	CDRH, Office	of Device Ev	aluation (ODE)	
8		ogical Device		
Prescription Use	OR		e -Counter Use	,
Prescription Use 7-4 (Per 21 CFR 801.109)	OR	Over-th	e -Counter Use	2